ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "fibrosis"

  • Abstract Number: 1860 • 2016 ACR/ARHP Annual Meeting

    Activating Transcription Factor 3 – a New Linkage Between Vasculopathy and Organ Fibrosis in Systemic Sclerosis

    Thomas Wohlfahrt1, Alina Soare2, Tatjana Mallano2, Morgane Gourlaouen3, Stephen Moss3, Britta Maurer4, Oliver Distler4, Tsonwin Hai5, Georg Schett2, Jörg Distler2 and Andreas Ramming2, 1Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 3Institute of Ophthalmology, Department of Cell Biology, University College London, London, United Kingdom, 4Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 5Department of Molecular and Cellular Biochemistry, The Ohio State University, Colombus, OH

    Background/Purpose: Since vascular manifestations such as Raynaud’s phenomenon and morphological changes on nailfold capillaroscopy often precede the onset of other clinical manifestations of systemic sclerosis…
  • Abstract Number: 1365 • 2015 ACR/ARHP Annual Meeting

    Innate Lymphoid Cells. New Players in Systemic Sclerosis Correlate with Extent of Skin and Lung Fibrosis

    Thomas Wohlfahrt1, Stefanie Weber1, Matthias Englbrecht2, Clara Dees3, Christian Beyer3, Oliver Distler4, Georg Schett1, Jorg HW Distler1,3 and Andreas Ramming1, 1Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Internal Medicine 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 3Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, 4Research of Systemic Autoimmune Diseases, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland

    Background/Purpose: Type 2 innate lymphoid cells (ILC2s), are recently identified as population of cells with lymphoid morphology lacking re-arranged antigen-specific receptors. Although findings in animal…
  • Abstract Number: 3008 • 2015 ACR/ARHP Annual Meeting

    Role of PTP4A1 Tyrosine Phosphatase in Systemic Sclerosis

    Cristiano Sacchetti1, Stephanie Stanford2, Yunpeng Bai3, Zhong-Yin Zhang4, Amin Gholami5, Gregory Seumois6, Maria Piera-Velazquez7, Sergio A. Jimenez8 and Nunzio Bottini1, 1Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 2Cell Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 3Indiana University, School of Medicine, Indianapolis, IN, 4Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, 5Bioinformatics Core, La Jolla Institute for Allergy and immunology, La Jolla, CA, 6Sequencing Facility, La Jolla Institute for Allergy and immunology, La Jolla, CA, 7Dermatology and Cutaneous Biology, Jefferson Medical College, Philadelphia, PA, 8Div Connective Tissue Diseases, Thomas Jefferson Univ, Philadelphia, PA

    Background/Purpose: Systemic sclerosis (SSc) is a multi-system autoimmune connective tissue disorder that leads to fibrosis of the skin and internal organs, resulting in significant patient…
  • Abstract Number: 1886 • 2015 ACR/ARHP Annual Meeting

    Myocardial Fibrosis Detected By Magnetic Resonance Imaging Is a Predictor of Heart Failure in Systemic Sclerosis (SSc) Patients

    Tatiana Sofia Rodriguez-Reyna1, Martha Morelos-Guzmán2, Pamela Mercado Velazquez3, Pablo Henrandez-Reyes4, Karla Montero-Duarte5, Cynthia Martinez-Reyes6, Carlos Reyes-Utrera6 and Carlos Nunez Alvarez3, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Radiology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 3Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico, 4Department of Cardiology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 5Department of Imaging and Radiology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 6Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico

    Background/Purpose: In previous studies we showed that prevalence of myocardial fibrosis in SSc patients is 45% and is associated to diffuse disease (dcSSc) and lower…
  • Abstract Number: 3010 • 2015 ACR/ARHP Annual Meeting

    Estrogens Inhibit the Profibrotic Effects of Transforming Growth Factor-Beta and Protect from the Development of Experimental Dermal Fibrosis

    Jerome Avouac1, Léa Baudoin2, Anne Cauvet2, Barbara Ruiz2 and Yannick Allanore3, 1Rheumatology A department and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, 2INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, 3Paris Descartes University, Rheumatology A department, Cochin Hospital, And Eular Scleroderma Trials And Research (EUSTAR) Board, Paris, France

    Background/Purpose: Systemic sclerosis (SSc) primarily affects postmenopausal women. This sex bias could partly be explained by the action of estrogens on the immune system and/or…
  • Abstract Number: 1888 • 2015 ACR/ARHP Annual Meeting

    There Is a Need for New Systemic Sclerosis Subset Criteria: A Content Analytic Approach

    Sindhu Johnson1, Medha Soowamber2, Jaap Fransen3, Dinesh Khanna4, Frank H.J. van den Hoogen5, Murray Baron6, Marco Matucci Cerinic7, Christopher P. Denton8, Thomas A. Medsger Jr.9, Patricia E. Carreira10, Gabriela Riemekasten11, Jorg HW. Distler12, Armando Gabrielli13, Virginia D. Steen14, Lorinda Chung15, Richard Silver16, John Varga17, Ulf Müller-Ladner18, Madelon C. Vonk19, Ulrich A. Walker20, Frank Wollheim21, Ariane L. Herrick22, Daniel E. Furst23, Lazlo Czirjak24, Otylia Kowal-Bielecka25, Francesco Del Galdo26, Maurizio Cutolo27, Nicolas Hunzelmann28, Charles Murray29, Ivan Foeldvari30, Luc Mouthon31, Nemanja Damjanov32, Bashar Kahaleh33, Tracy M. Frech34, Shervin Assassi35, Lesley Ann Saketkoo36 and Janet E. Pope37, 1Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, 2Rheumatology, University of Toronto/ Toronto Western Hospital, Toronto, ON, Canada, 3Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, 4Medicine, University of Michigan, Ann Arbor, MI, 5Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 6Pavillion A, Rm 216, Jewish General Hospital, Montreal, QC, Canada, 7Department of BioMedicine, Division of Rheumatology, Transition Unit, University of Florence, Firenze, Italy, 8Centre for Rheumatology, Royal Free Hospital, London, United Kingdom, 9Medicine/Rheumatology, Univ of Pittsburgh, Pittsburgh, PA, 10Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 11Rheumatology, Human medicine, BERLIN, Germany, 12Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, 13Clinica Medica, Università Politecnica delle Marche, Ancona, Italy, 14Rheumatology, Georgetown University Medical Center, Washington, DC, 15Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 16Div Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 17Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 18Rheumatology, Internal Medicine, Bad Nauheim, Germany, 19Rheumatology, Rheumatology, Nijmegen, Netherlands, 20Rheumatology, Systemic Sclerosis, Basel, Switzerland, 21Rheumatology, Lund University Hospital, Lund, Sweden, 22Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 23Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 24University of Pécs Medical Center, Pécs, Hungary, 25Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, 26University of Leeds, Leeds, United Kingdom, 27Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, 28Department of Dermatology, University of Cologne, Cologne, Germany, 29Department of Gastroenterology, Royal Free Hospital, London, United Kingdom, 30Rheumatology, Hamburg, Germany, 31Department of Internal Medicine, Department of Internal Medicine, Cochin Hospital, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Paris-Descartes University, AP-HP, Paris, France, 32Resavska 69, Institute of Rheumatology, Belgrade, Serbia, 33Medicine/Rheumatology, The University of Toledo, Toledo, OH, 34Div of Rheumatology, University of Utah Medical Ctr, Salt Lake City, UT, 35Rheumatology, University of Texas Medical School at Houston, Houston, TX, 36Tulane University Lung Center, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, 37University of Western Ontario, London, ON, Canada

    Background/Purpose: Systemic sclerosis (SSc) is a family of diseases unified by the presence of immune activation, vasculopathy and fibrosis. The concept of SSc subsets cannot…
  • Abstract Number: 3012 • 2015 ACR/ARHP Annual Meeting

    Over-Expression of Ubiquitin-Specific Peptidases in Systemic Sclerosis Fibroblasts Increases Responses to TGF-Beta

    Christine Galant, Joëlle Marchandise, Julie Ducreux, Maria Stoenoiu, Frédéric A. Houssiau and Bernard R. Lauwerys, Pôle de pathologies rhumatismales inflammatoires et systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium

    Background/Purpose: Ubiquitination of proteins leads to their degradation by the proteasome, and is regulated by a small number of ubiquitin ligases, and a large number…
  • Abstract Number: 1892 • 2015 ACR/ARHP Annual Meeting

    Impact of Cardiac Magnetic Resonance Imaging with T1 Mapping and Multi-b Value Diffusion-Weighted Sequences in Systemic Sclerosis for the Assessment of Myocardial Microscopic Fibrosis and Perfusion

    Benjamin Terrier1, Hervé Gouya2, Alice Berezne1, Alexis Regent3, Pascal Cohen1, Loïc Guillevin4, Claire Le Jeunne5, Paul Legmann2, Olivier Vignaux6 and Luc Mouthon7, 1Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, 2AP-HP Cochin Hospital, Department of Radiology B, Paris, France, 3Service de médecine interne, Hôpital Cochin, Paris, France, 4Internal Medicine, Hopital Cochin, Paris, France, 5Department of Internal Medicine, Hotel-Dieu Hospital, AP-HP, Paris, Paris, France, 6Radiology, Cochin University Hospital, Paris, France, 7Department of Internal Medicine, Department of Internal Medicine, Cochin Hospital, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Paris-Descartes University, AP-HP, Paris, France

    Background/Purpose: Systemic sclerosis (SSc) is a complex disease associating vasculopathy, cutaneous and visceral fibrosis, and autoimmunity. Myocardial microscopic fibrosis may occur and potentially lead to…
  • Abstract Number: 3013 • 2015 ACR/ARHP Annual Meeting

    Adipose Loss of Co-Repressor Ncor Attenuates Bleomycin-Induced Skin Fibrosis By Enhancing PPAR-Gamma Signaling

    Benjamin Korman1, Roberta Goncalves Marangoni1, Warren Tourtellotte2 and John Varga3, 1Division of Rheumatology, Northwestern University, Chicago, IL, 2Department of Pathology, Ward, Northwestern University, Chicago, IL, 3Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL

    Background/Purpose: The adipogenesis master regulator PPAR-gamma (PPARg) is regulated by repressors such as NCoR. Systemic sclerosis (SSc) is associated with impaired PPARg expression and function…
  • Abstract Number: 1907 • 2015 ACR/ARHP Annual Meeting

    Inhibition of Phosphodiesterase 4 (PDE4) Reduces Dermal Fibrosis By Interfering with the Release of Pro-Fibrotic Cytokines from M2-Macrophages

    Christiane Maier, Christian Beyer, Jeorg HW Distler and Georg Schett, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: PDE4 catalyses the breakdown of the second messengers cAMP and cGMP to modulate intracellular effects. PDE4 is mainly expressed in inflammatory cells, and its…
  • Abstract Number: 1918 • 2015 ACR/ARHP Annual Meeting

    Pharmacologic Targeting of Mitochondrial Dysfunction in Systemic Sclerosis: Enhanced SIRT3 Signaling

    Kaname Akamata1, Mitra Bhattacharyya1, Mahesh Gupta2, Jack Arbiser3, David Kamp4, Jun Wei1 and John Varga1, 1Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, 2University of Chicago, Departments of Surgery, Chicago, IL, 3Department of Dermatology, Emory University School of Medicine Winship Cancer Institute Atlanta Veterans Administration Health Center, Atlanta, GA, 4Department of Medicine, Division of Pulmonary & Critical Care Medicine, Jesse Brown VA Medical Center and Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose: Recent evidences suggest that cytosolic and mitochondrial reactive oxygen species (ROS), play pivotal roles in modulating TGF-β-induced profibrotic responses and are implicated in pathogenesis…
  • Abstract Number: 1919 • 2015 ACR/ARHP Annual Meeting

    Genetic Deletion of Toll-like Receptor 4 (Tlr4) Abrogates TGF-β1-Induced Endothelial-to-Mesenchymal Transition (EndoMT) in Murine Pulmonary Endothelial Cells

    Peter J. Wermuth1 and Sergio A. Jimenez2, 1Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, 2Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA

    Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease of unknown etiology whose pathogenesis involves the regulation of a diverse range of molecular pathways. The…
  • Abstract Number: 1925 • 2015 ACR/ARHP Annual Meeting

    Interleukin-35 Is Upregulated in Systemic Sclerosis and Its Serum Levels Are Increased in Early Disease

    Michal Tomcík1, Pawel Zerr2, Katrin Palumbo-Zerr2, Hana Storkanova1, Hana Hulejova3, Maja Spiritovic4, Ondrej Kodet5, Jiri Stork5, Radim Becvar1, Jiri Vencovsky1, Karel Pavelka6, Maria Filkova7, Jorg HW Distler2 and Ladislav Senolt8, 1Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 2Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 3Institute of Rheumatology and Department of Rheumatology, Prague, Czech Republic, 4Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, 5Department of Dermatology and Venereology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 6Charles University, Prague, Czech Republic, 7Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 8Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose: Interleukin-35 (IL-35) is the most recent addition to the IL-12 family, which also comprises IL-12, IL-23 and IL-27. IL-35 consists of two chains, p35/IL-12a…
  • Abstract Number: 1926 • 2015 ACR/ARHP Annual Meeting

    Wnt5a Activates Wnt/PCP-Signaling to Promote Fibroblast Activation and Fibrosis

    Chih-Wei Chen1, Neng-Yu Lin1, Yun Zhang1, Jingang Huang1, Katrin Palumbo-Zerr1, Alexandra Schambony2, Christian Beyer1, Georg Schett1 and Jeorg HW Distler1, 1Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Biology, Development Biology, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: While canonical Wnt/beta-catenin signaling has been identified as a core pathway of fibrosis in SSc, non-canonical Wnt signaling pathways have not yet been analyzed.…
  • Abstract Number: 1927 • 2015 ACR/ARHP Annual Meeting

    Salinomycin Induces Potent Suppression of TGF-β1-Mediated Expression of Profibrotic Genes in Cultured Dermal Fibroblasts from Normal Donors and from Donors with Systemic Sclerosis (SSc): A Novel Anti-Fibrotic Treatment for Tissue Fibrosis in SSc

    Peter J. Wermuth1 and Sergio A. Jimenez2, 1Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, 2Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA

    Background/Purpose: Activated myofibroblasts are the primary mediators of the excessive synthesis and deposition of collagens and other extracellular matrix (ECM) macromolecules during the pathogenesis of…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology